229 related articles for article (PubMed ID: 25700579)
1. [Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente].
Azpiri-López JR; Assad-Morell JL; Ponce de León-Martínez E; Monreal-Puente R; Dávila-Bortoni A; Vázquez-Díaz LA; Treviño-Frutos RJ; Barrera-Oranday F; Del Angel-Soto JG; Martínez JG; Arellano-Torres M
Arch Cardiol Mex; 2015; 85(2):154-7. PubMed ID: 25700579
[TBL] [Abstract][Full Text] [Related]
2. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
[TBL] [Abstract][Full Text] [Related]
4. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
[TBL] [Abstract][Full Text] [Related]
5. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
[TBL] [Abstract][Full Text] [Related]
6. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
Esler M
J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
[TBL] [Abstract][Full Text] [Related]
7. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.
Esler MD; Krum H; Schlaich M; Schmieder RE; Böhm M; Sobotka PA;
Circulation; 2012 Dec; 126(25):2976-82. PubMed ID: 23248063
[TBL] [Abstract][Full Text] [Related]
8. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.
Kandzari DE; Bhatt DL; Sobotka PA; O'Neill WW; Esler M; Flack JM; Katzen BT; Leon MB; Massaro JM; Negoita M; Oparil S; Rocha-Singh K; Straley C; Townsend RR; Bakris G
Clin Cardiol; 2012 Sep; 35(9):528-35. PubMed ID: 22573363
[TBL] [Abstract][Full Text] [Related]
9. [Renal artery denervation for treating refractory hypertension].
Benamer H; Louvard Y; Garot P; Unterseeh T; Hovasse T; Lefèvre T; Chevalier B; Morice MC
Ann Cardiol Angeiol (Paris); 2011 Dec; 60(6):354-60. PubMed ID: 22040858
[TBL] [Abstract][Full Text] [Related]
10. Renal sympathetic denervation in the aftermath of Symplicity HTN-3.
Kjeldsen SE; Fadl Elmula FE; Persu A; Jin Y; Staessen JA
Blood Press; 2014 Oct; 23(5):256-61. PubMed ID: 25212427
[No Abstract] [Full Text] [Related]
11. Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial.
Ruilope LM; Arribas F
Rev Esp Cardiol (Engl Ed); 2014 Nov; 67(11):881-2. PubMed ID: 25242659
[No Abstract] [Full Text] [Related]
12. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
Epstein M; de Marchena E
J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995
[TBL] [Abstract][Full Text] [Related]
13. Renal denervation in treatment-resistant hypertension: a reappraisal.
Persu A; Jin Y; Fadl Elmula FE; Renkin J; Høieggen A; Kjeldsen SE; Staessen JA
Curr Opin Pharmacol; 2015 Apr; 21():48-52. PubMed ID: 25601357
[TBL] [Abstract][Full Text] [Related]
14. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials.
Pocock SJ; Bakris G; Bhatt DL; Brar S; Fahy M; Gersh BJ
J Am Coll Cardiol; 2016 Nov; 68(18):2016-2025. PubMed ID: 27788856
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure lowering effect of renal sympathetic denervation or placebo? - building expectations for Symplicity-HTN 3.
Kjeldsen SE; Narkiewicz K; Oparil S; Hedner T
Blood Press; 2013 Oct; 22(5):279-81. PubMed ID: 24059787
[No Abstract] [Full Text] [Related]
16. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
[TBL] [Abstract][Full Text] [Related]
17. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial.
Kario K; Bhatt DL; Kandzari DE; Brar S; Flack JM; Gilbert C; Oparil S; Robbins M; Townsend RR; Bakris G
Circ J; 2016 May; 80(6):1404-12. PubMed ID: 27118620
[TBL] [Abstract][Full Text] [Related]
18. Renal denervation--hypes and hopes.
Lewek J; Kaczmarek K; Pokushalov E; Romanov A; Cygankiewicz I; Ptaszynski P
Cardiovasc Ther; 2015 Jun; 33(3):141-4. PubMed ID: 25786785
[TBL] [Abstract][Full Text] [Related]
19. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.
Yerasi C; Baker NC; Jonnalagadda AK; Torguson R; Singh S; Vies J; Waksman R
J Am Soc Hypertens; 2015 Dec; 9(12):959-65. PubMed ID: 26687550
[TBL] [Abstract][Full Text] [Related]
20. [Percutaneous renal denervation as a new method of treatment of resistant arterial hypertension].
Mach-Jamińska A; Sułowicz W
Przegl Lek; 2012; 69(11):1215-9. PubMed ID: 23646450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
